ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None20262025202420232022202120202019 Date Title 16 June 2026 Becoming a substantial holder 12 June 2026 Ceasing to be a substantial holder 02 June 2026 ASX CEO Connect Presentation 30 April 2026 Quarterly Activities/Appendix 4C Cash Flow Report 29 April 2026 Patient Recruitment Target Achieved in CLBP Pivotal Trial 16 April 2026 Appendix 3Y for Gregory George 16 April 2026 Notification of cessation of securities - MSB 16 April 2026 Notification regarding unquoted securities - MSB 16 April 2026 Application for quotation of securities - MSB 16 April 2026 Notification regarding unquoted securities - MSB 15 April 2026 Acquires CAR Platform for Precision-Enhanced Cell Products 08 April 2026 Mesoblast R&D Day Presentation 08 April 2026 Mesoblast R&D Day Features Commercial & Blockbuster Programs 08 April 2026 Application for quotation of securities - MSB 08 April 2026 Cleansing Notice 07 April 2026 Proposed issue of securities - MSB 07 April 2026 Ryoncil Net Revenue for the Quarter Increases to US$30.3M 20 March 2026 Appendix 3Ys - S Itescu, E Rose, G George and L Cobley 20 March 2026 Notification regarding unquoted securities - MSB 18 March 2026 Mesoblast to Host R&D Day on April 8, 2026 12 March 2026 Replacement Appendix 3Y for Gregory George 12 March 2026 Appointment of Clinical Development and Medical Affairs Head 10 March 2026 Becoming a substantial holder 10 March 2026 Appendix 3Y for Gregory George 09 March 2026 Change in substantial holding 27 February 2026 Ryoncil Profits Underpinning Substantial Growth Pipeline 27 February 2026 Corporate Presentation and Half Year Financial Results 27 February 2026 Half Year Report and Accounts (including Appendix 4D) 20 February 2026 Mesoblast 2026 Half Year Financial Results Webcast 12 February 2026 High Survival Rates with Ryoncil in SR-aGvHD EIND Program 09 February 2026 Becoming a substantial holder 29 January 2026 Quarterly Activities/Appendix 4C Cash Flow Report 27 January 2026 Real World Experience with Ryoncil Shows 84% Early Survival 27 January 2026 Ceasing to be a substantial holder 27 January 2026 Becoming a substantial holder 19 January 2026 FDA Confirms Path to Approval for CLBP 15 January 2026 Notification of cessation of securities - MSB 15 January 2026 Notification regarding unquoted securities - MSB 13 January 2026 Notification regarding unquoted securities - MSB 13 January 2026 Application for quotation of securities - MSB 13 January 2026 Appendix 3Y for Eric Rose 12 January 2026 Appendix 3Y for Lyn Cobley 09 January 2026 Ryoncil Sales for the Quarter Increase 60% to US$35.1M 06 January 2026 Appendix 3Y for Gregory George 06 January 2026 Notification of cessation of securities - MSB 02 January 2026 Mesoblast Announces Changes to Board of Director Roles
